A Phase 3 Randomized Controlled Trial of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus

被引：0

作者：

Furie, Richard ^{[1
]}

Morand, Eric ^{[2
]}

Bruce, Ian ^{[3
]}

Manzi, Susan ^{[4
]}

Kalunian, Kenneth ^{[5
]}

Vital, Edward ^{[6
]}

Lawrence-Ford, Theresa ^{[7
]}

Gupta, Ramesh ^{[8
]}

Hiepe, Falk ^{[9
]}

Santiago, Mittermayer ^{[10
]}

Brohawn, Philip ^{[11
]}

Berglind, Anna ^{[12
]}

Tummala, Raj ^{[11
]}

机构：

[1] Zucker Sch Med Hofstra Northwell, New York, NY USA

[2] Monash Univ, Melbourne, Vic, Australia

[3] Univ Manchester, Manchester, Lancs, England

[4] Allegheny Hlth Network, Pittsburgh, PA USA

[5] Univ Calif San Diego, Div Rheumatol Allergy & Immunol, La Jolla, CA 92093 USA

[6] Univ Leeds, Leeds, W Yorkshire, England

[7] North Georgia Rheumatol, Lawrenceville, GA USA

[8] Baptist Mem Hosp, Memphis, TN 38146 USA

[9] Charite, Berlin, Germany

[10] Bahiana Sch Med & Publ Hlth, Salvador, BA, Brazil

[11] AstraZeneca, Gaithersburg, MD USA

[12] AstraZeneca, Gothenburg, Sweden

来源：

ARTHRITIS & RHEUMATOLOGY | 2019年 / 71卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1763

引用

页数：3

共 50 条

[31] Effects of atacicept on disease activity in patients with moderate to severe systemic lupus erythematosus: APRIL-SLE randomized trial
Isenberg, David
Li, Yong
Wax, Stephen
Wofsy, David
Gordon, Caroline
[J]. ARTHRITIS RESEARCH & THERAPY, 2014, 16
[32] Effects of atacicept on disease activity in patients with moderate to severe systemic lupus erythematosus: APRIL-SLE randomized trial
David Isenberg
Yong Li
Stephen Wax
David Wofsy
Caroline Gordon
[J]. Arthritis Research & Therapy, 16
[33] EFFECTS OF ATACICEPT ON DISEASE ACTIVITY IN PATIENTS WITH MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS: APRIL-SLE RANDOMIZED TRIAL
Gordon, C.
Isenberg, D.
Li, Y.
Wax, S.
Wofsy, D.
Rossi, C. Pena
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 77 - 77
[34] FLARE ASSESSMENTS IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS TREATED WITH ANIFROLUMAB IN 2 PHASE 3 TRIALS
Furie, R.
Morand, E. F.
Askanase, A.
Vital, E.
Kalyani, R.
Abreu, G.
Pineda, L.
Tummala, R.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1024 - 1025
[35] ANIFROLUMAB, AN ANTI-INTERFERON-ALPHA RECEPTOR MONOCLONAL ANTIBODY, IN MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Furie, R.
Merrill, J. T.
Werth, V. P.
Khamashta, M.
Kalunian, K.
Brohawn, P.
Illei, G.
Drappa, J.
Wang, L.
Yoo, S.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 168 - 168
[36] Fatigue in systemic lupus erythematosus: a randomized controlled trial of exercise
Tench, CM
McCarthy, J
McCurdie, I
White, PD
D'Cruz, DP
[J]. RHEUMATOLOGY, 2003, 42 (09) : 1050 - 1054
[37] Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus (vol 60, pg 5397, 2021)
Furie, Richard A.
Bruce, Ian N.
Dorner, Thomas
Leon, Manuel Gustavo
Leszczynski, Piotr
Urowitz, Murray
Haier, Birgit
Jimenez, Teri
Brittain, Claire
Liu, Jiajun
Barbey, Catherine
Stach, Christian
[J]. RHEUMATOLOGY, 2022, 62 (01) : 486 - 486
[38] Anifrolumab, an Anti-Interferon Alpha Receptor Monoclonal Antibody, in Moderate to Severe Systemic Lupus Erythematosus (SLE)
Furie, Richard
Merrill, J. T.
Werth, V. P.
Khamashta, M.
Kalunian, K.
Brohawn, P.
Illei, G.
Drappa, J.
Wang, L.
Yoo, S.
[J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
[39] ANIFROLUMAB, AN ANTI-INTERFERON-ALPHA RECEPTOR MONOCLONAL ANTIBODY, IN MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Furie, R.
Merrill, J.
Werth, V.
Khamashta, M.
Kalunian, K.
Brohawn, P.
Illei, G.
Drappa, J.
Wang, L.
Yoo, S.
[J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (04) : S4 - S4
[40] Anifrolumab: first biologic approved in the EU not restricted to patients with a high degree of disease activity for the treatment of moderate to severe systemic lupus erythematosus
Gensous, Noemie
Lazaro, Estibaliz
Blanco, Patrick
Richez, Christophe
[J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2024, 20 (01) : 21 - 30

← 1 2 3 4 5 →